89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.

89bio, Inc.

89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company’s lead product candidate, BIO89-100, is a specifically engineered glycoPEGylated analog of FGF21. BIO89-100 is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). Recent Phase 1b/2a data show BIO89-100 demonstrated a favorable safety and tolerability profile and robust reductions in liver fat and key lipid markers when dosed weekly or once every two weeks in patients with NASH. BIO89-100 is currently in a Phase 2 trial for the treatment of SHTG. 89bio is headquartered in San Francisco with operations in Herzliya, Israel.

Our culture is best described by our values:
•	Always putting the patient first
•	Operating with the highest integrity and ethical standards at all times
•	Being authentic in all our transactions
•	Acting as a team – collaborating, respecting and caring for one another
•	Being entrepreneurial and passionate in our tasks
•	Being scientific and rational in our thought process and decision-making


K2 HealthVentures

Longitude Capital

OrbiMed

Pontifax

RA Capital Management

89bio

It’s #NationalTriglycerides day: do you know your numbers? Our #triglyceride levels play a key role in living a healthy lifestyle. Elevated triglyceride levels can increase the risk of several conditions, including #CardiovascularDisease and #MetabolicSyndrome.
 
Learn more about Severe Hypertriglyceridemia or #SHTG and 89bio’s mission to develop treatment options: https://lnkd.in/gE7AwYWu

Our investigational FGF21 analog has received the European Medicines Agency Priority Medicines (PRIME) status in patients with non-cirrhotic #MASH with fibrosis and MASH with compensated cirrhosis. This designation was supported by the positive data from our Phase 2b ENLIVEN trial. 

Learn more about the PRIME status and what this means for us: https://lnkd.in/gSDeAeAK

#NASH #MASH #Innovation #the89way
 


We’re excited to announce the initiation of our Phase 3 ENLIGHTEN-Fibrosis trial, which will evaluate the efficacy and safety of our investigational fibroblast growth factor 21 (FGF21) analog in patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis. This new phase marks an inspiring milestone in our progress toward developing meaningful medicines. 

To learn more, read our release: https://lnkd.in/eG6UuC-P 
 
#NASH #MASH #ClinicalTrials #Innovation

Join our growing team at 89bio! Our team of experts embrace a start-up mindset, cultivate an entrepreneurial spirit and are driven to create the best opportunities for our hard-working team of 89ers. If this sounds like you, and you’re passionate about developing innovative therapies for #CardioMetabolic diseases, check out our open roles and learn more about #the89way: https://lnkd.in/gnP5i8-n

#HealthcareJobs #Hiring

	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue
cost of revenue						273K -
gross profit						-273K -
selling and marketing expenses						-273K -
general and administrative expenses	1.48M -	5.29M 257.46%	13.16M 148.51%	19.41M 47.56%	21.45M 10.51%	28.97M 35.06%
selling general and administrative expenses	1.48M -	5.29M 257.46%	13.16M 148.51%	19.41M 47.56%	21.45M 10.51%	28.70M 33.79%
research and development expenses	13.68M -	21.35M 56.03%	36.20M 69.58%	70.33M 94.29%	80.80M 14.88%	122.23M 51.28%
other expenses	-986K -	-30.56M 2,999.59%	-203K 99.34%	-526K 159.11%	242K 146.01%
cost and expenses	15.16M -	26.64M 75.70%	49.35M 85.27%	89.74M 81.83%	102.25M 13.94%	151.20M 47.88%
operating expenses	15.16M -	26.64M 75.70%	49.35M 85.27%	89.74M 81.83%	102.25M 13.94%	150.93M 47.61%
interest expense					1.92M -	3.59M 86.58%
ebitda	-15.16M -	-26.64M 75.77%	-49.35M 85.27%	-89.74M 81.83%	-102.25M 13.94%	-150.93M 47.61%
operating income	-15.16M -	-26.64M 75.70%	-49.35M 85.27%	-89.74M 81.83%	102.25M 213.94%	-151.20M 247.88%
depreciation and amortization	6K -	17K 183.33%	60K 252.94%	79K 31.67%	-204.50M 258,958.23%	273K 100.13%
total other income expenses net	-986K -	-30.56M 2,999.59%	-203K 99.34%	-526K 159.11%	-204.26M 38,731.94%	12.88M 106.31%
income before tax	-16.15M -	-57.20M 254.24%	-49.56M 13.36%	-90.27M 82.15%	-102.01M 13.00%	-138.32M 35.60%
income tax expense	28K -	218K 678.57%	-59K 127.06%	-147K 149.15%	19K 112.93%	3.87M 20,252.63%
net income	-16.18M -	-57.42M 254.97%	-49.50M 13.79%	-90.12M 82.07%	-102.03M 13.21%	-142.19M 39.37%
weighted average shs out	4.58M -	2.34M 48.86%	16.09M 586.28%	20.10M 24.93%	34.81M 73.18%	71.17M 104.48%
weighted average shs out dil	4.58M -	2.34M 48.86%	16.09M 586.28%	20.10M 24.93%	34.81M 73.18%	71.17M 104.48%
eps	-3.53 -	-24.49 593.77%	-3.08 87.42%	-4.48 45.45%	-2.93 34.60%	-2 31.74%
epsdiluted	-3.53 -	-24.49 593.77%	-3.08 87.42%	-4.48 45.45%	-2.93 34.60%	-2 31.74%

COM:89BIO

89Bio

Last Close

7.98

21/11 21:00

Market Cap

851.02M

Beta: -

Volume Today

468.57K

Avg: -

Preview